Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy

Some Postmenopausal Women From Breast Cancer Can Protect Hormonal Therapy.
In a find that seems to marker the prevailing wisdom that any form of hormone replacement psychoanalysis raises the risk of breast cancer, a new look at some old data suggests that estrogen-only hormone group therapy might protect a small subset of postmenopausal women against the disease. "Exogenous estrogen such as hormone analysis is actually protective" in women who have a low risk for developing tit tumors, said study author Dr Joseph Ragaz, a medical oncologist and clinical professor in the School of Population & Public Health at the University of British Columbia in Vancouver. With his colleagues, Ragaz took another manner at details from the Women's Health Initiative (WHI) study, a jingoistic trial that has focused on ways to prevent breast and colorectal cancer, as well as sentiment disease and fracture risk, in postmenopausal women.

The team planned to present its findings Thursday at the San Antonio Breast Cancer Symposium in Texas. Research presented at medical meetings is not analyzed by home experts, ill-matched studies that appear in peer-reviewed medical journals, and all such findings should be considered preliminary. Launched in 1991, the WHI includes more than 161000 US women between the ages of 50 and 79.

Two groups were area of the thorn in the flesh - women who had had hysterectomies and took estrogen desolate as hormone replacement therapy and a group that took estrogen plus progestin hormone replacement therapy. The mix therapy trial was halted in 2002 after it became clear those women were at increased chance for heart disease and breast cancer.

In the new look at the estrogen-only group "we looked at women who did not have high-risk features". They found that women with no earlier history of benign teat disease had a 43 percent reduction breast cancer risk on estrogen; women with no house history with a first-degree relative with breast cancer had a 32 percent risk reduction and women without past hormone use had a 32 percent reduced risk.

Overall, the 10000-plus participants had a 20 percent reduction in soul cancer risk, a reduction that approached statistical significance. After their review, Ragaz said they concluded that using estrogen alone, exceptionally if begun in women less than 60 who don't have a uterus, can cure reduce breast cancer risk.

The new review did not receive sedative company funding. "Women without a uterus should be totally safe and benefit a great deal with estrogen-only use ". Yet, more into or is needed to find the best treatment regimen, decide who are the ideal candidates and to figure out just why the estrogen only reduces risk in some women.

The findings don't actually include anything new, said Dr Rowan Chlebowski, a WHI investigator who is himself of medical oncology/hematology at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. The same results were published back in 2006, when the WHI investigators reported on the estrogen-only arm of the study. "These results have been around for a extensive while of time". But, he added that "you have to be guarded about interpreting subgroups".

To say estrogen is careful is a little strong. The overall reduction in breast cancer risk found among the 10000 participants - 20 percent - didn't establish significance from a statistical purport of view. When looked at by subgroups - those with no previous benign breast disease, those with no one-time HRT use, those with no first-degree relative with breast cancer - the reductions were significant muscleadvance.herbalyzer.com. "The tidings is pretty much unchanged by this new review ," he said, adding "I guesstimate it will get people to look at the data again".